Login / Signup

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.

Colleen K LooKevin Thien Anh HoangDavid BartonBernhard T BauneNatalie T MillsPaul FitzgeraldPaul GlueShanthi SarmaVeronica Galvez-OrtizDusan Hadzi-PavlovicAngelo AlonzoVanessa DongDonel MartinStevan NikolinPhilip B MitchellMichael BerkGregory CarterMaree HackettJohn LeydenSean D HoodAndrew A SomogyiKyle LapidusElizabeth StrattonKirsten GainsfordDeepak GargNicollette L R ThorntonCélia FourrierKaryn RichardsonDemi RozakisAnish ScariaCathrine MihalopoulosMary Lou ChattertonWilliam M McDonaldPhilip BoycePaul E HoltzheimerF Andrew KozelPatricio Riva-PosseAnthony Rodgers
Published in: The British journal of psychiatry : the journal of mental science (2023)
Adequately dosed subcutaneous racemic ketamine was efficacious and safe in treating TRD over a 4-week treatment period. The subcutaneous route is practical and feasible.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • study protocol
  • open label
  • phase iii
  • phase ii
  • pain management
  • depressive symptoms
  • randomized controlled trial
  • sleep quality
  • physical activity